Peter Schmid
Queen Mary University of London(GB)Barts Health NHS Trust(GB)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies
Most-Cited Works
- → Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer(2018)4,261 cited
- → Pembrolizumab for Early Triple-Negative Breast Cancer(2020)2,940 cited
- → Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial(2020)1,740 cited
- → Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial(2019)1,171 cited
- → Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer(2022)998 cited
- → Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer